Research and innovation are integral to the advancement of medical knowledge and improvements in clinical care. While this progress is excellent for patients and cardiovascular care, the pace is accelerating and the landscape ever more competitive. It thus mandates academic institutions and leading-edge hospitals to organize research and innovation endeavors deliberately or risk being left behind. Modern research is incredibly complex in concept and technology, and the ability to make high-impact observations is no longer readily within the reach of a single investigator, but requires a sophisticated team.
Research teams of today and tomorrow will need to bring together diverse technology, scientific expertise, in-depth observations, and large datasets, to derive fundamental new insights. The University of Ottawa Heart Institute developed a new research strategic plan for the entire Ottawa region, to fast track innovation to impact. Brainstorming sessions lead to cutting-edge ideas that translate to interdisciplinary proposals that are the core activities of the Innovation Hubs. Patient partners are also critical to bring into focus the priorities from their point of view and what the research results will mean for their lives.
Therefore, the research teams of the future will need to be multidisciplinary, nimble, efficient, and outcome-oriented, accelerating excellence in care beyond imagination today.
This is a preview of subscription content, log in to check access.
Nguyen HV, de Oliveira C, Wijeysundera HC, Wong WW, Woo G, Grootendorst P, et al. Canada's contribution to global research in cardiovascular diseases. Can J Cardiol. 2013;29:742–6.CrossRefGoogle Scholar
de Oliveira C, Nguyen VH, Wijeysundera HC, Wong WW, Woo G, Liu PP, et al. How much are we spending? The estimation of research expenditures on cardiovascular disease in Canada. BMC Health Serv Res. 2012;12:281.CrossRefGoogle Scholar
de Oliveira C, Nguyen HV, Wijeysundera HC, Wong WW, Woo G, Grootendorst P, et al. Estimating the payoffs from cardiovascular disease research in Canada: an economic analysis. CMAJ Open. 2013;1:E83–90.CrossRefGoogle Scholar
Favaloro RG. Saphenous vein autograft replacement of severe segmental coronary artery occlusion: operative technique. Ann Thorac Surg. 1968;5:334–9.CrossRefGoogle Scholar
Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–80.CrossRefGoogle Scholar
Webb JG, Chandavimol M, Thompson CR, Ricci DR, Carere RG, Munt BI, et al. Percutaneous aortic valve implantation retrograde from the femoral artery. Circulation. 2006;113:842–50.CrossRefGoogle Scholar
Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364:2187–98.CrossRefGoogle Scholar
Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376:41–51.CrossRefGoogle Scholar
Suhr OB, Coelho T, Buades J, Pouget J, Conceicao I, Berk J, et al. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis. 2015;10:109.CrossRefGoogle Scholar